ストックスクリーナーアプリを入手
1.00
6.26%
0.0589
アフターアワーズ：
1.00
前日終値:
$0.9411
開ける：
$0.9699
24時間の取引高:
2.53M
Relative Volume:
0.57
時価総額：
$24.63M
収益：
-
当期純損益:
$-31.11M
株価収益率:
-0.4202
EPS:
-2.38
ネットキャッシュフロー:
$-28.18M
1週間 パフォーマンス:
-9.09%
1か月 パフォーマンス:
-29.58%
6か月 パフォーマンス:
-72.90%
1年 パフォーマンス:
-72.83%
1日の値動き範囲:
$0.941
$1.02
1週間の範囲:
$0.8637
$1.045
52週間の値動き範囲:
$0.8637
$6.00
Tempest Therapeutics Inc Stock (TPST) Company Profile
名前
Tempest Therapeutics Inc
セクター
電話
415-798-8589
住所
2000 SIERRA POINT PARKWAY, BRISBANE
Tempest Therapeutics Inc (TPST) 最新ニュース
TPST stock touches 52-week low at $0.91 amid market challenges - Investing.com UK
Take off with Tempest Therapeutics Inc (TPST): Get ready for trading - SETE News
Market Momentum: Tempest Therapeutics Inc (TPST) Registers a 4.39 Increase, Closing at 1.07 - The Dwinnex
TPST stock touches 52-week low at $0.92 amid market challenges By Investing.com - Investing.com South Africa
Tempest Therapeutics Inc (TPST) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Tempest Therapeutics maintains stock target, sector outperform rating - Investing.com
Tempest Therapeutics maintains stock target, sector outperform rating By Investing.com - Investing.com South Africa
TPST stock touches 52-week low at $0.92 amid market challenges - Investing.com
Was Tempest Therapeutics Inc (TPST)’s session last reading good? - US Post News
Tempest Therapeutics Inc [TPST] Stock trading around $1.10 per share: What’s Next? - The DBT News
Tempest Therapeutics Inc [NASDAQ: TPST] Sees Decrease in Stock Value - Knox Daily
Tempest Therapeutics shares retain Buy rating post Roche deal - Investing.com
Market Momentum: Tempest Therapeutics Inc (TPST) Registers a -18.52 Decrease, Closing at 1.10 - The Dwinnex
Tempest Therapeutics Inc (TPST) Stock: A Year of Market Fluctuations - The InvestChronicle
TPST’s price-to-free cash flow ratio: What it means for investors - US Post News
Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study - XM
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday? - Yahoo Finance
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Tempest Therapeutics to Advance Liver Cancer Drug to Phase 3 Trial with Roche; Shares Jump Pre-Bell - Marketscreener.com
Tempest stock gains on Roche collaboration (NASDAQ:TPST) - Seeking Alpha
Tempest Therapeutics partners with Roche on cancer trial - Investing.com
Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial - ForexTV.com
Tempest Therapeutics, Inc Enters into Master Clinical Supply Agreement with F. Hoffmann-La Roche Ltd. to Which Roche Will Supply Roche?S Atezolizumab - Marketscreener.com
Tempest Extends Limited Duration Stockholder Rights Plan - GlobeNewswire
Tempest Announces Agreement with Roche to Support - GlobeNewswire
Healthy Upside Potential: Tempest Therapeutics Inc (TPST) - SETE News
TPST Shares Experience Surge in Value - Knox Daily
How to interpret Tempest Therapeutics Inc (TPST)’s stock chart patterns - US Post News
Scotiabank initates Tempest Therapeutics Inc (TPST) rating to a Sector outperform - Knox Daily
Quarterly Metrics: Quick and Current Ratios for Tempest Therapeutics Inc (TPST) - The Dwinnex
Sigourney Weaver to star in Jamie Lloyd's 'The Tempest' this fall - LondonTheatre.co.uk
A Closer Look at Tempus AI Inc. (TEM) Stock Gains - The InvestChronicle
The Tempest cast announced to join Sigourney Weaver at the Theatre Royal Drury Lane in London - WestEndTheatre.com
See Who's Joining Sigourney Weaver in West End The Tempest - Playbill
Davidson Kempner Capital Management LP Acquires New Shares in Tempus AI, Inc. (NASDAQ:TEM) - MarketBeat
Full Cast Announced for The Tempest at Theatre Royal Drury Lane - London Theatre 1
Gavin & Stacey star joins Sigourney Weaver in The Tempest - RadioTimes
The Tempest with Sigourney Weaver at Theatre Royal Drury Lane announces complete casting - WhatsOnStage.com
Full cast announced for Jamie Lloyd Company’s THE TEMPEST at Theatre Royal Drury Lane - West End Best Friend
Brokerages Set Tempus AI, Inc. (NASDAQ:TEM) Price Target at $45.56 - MarketBeat
Tempus AI (NASDAQ:TEM) Shares Gap Up to $50.09 - Defense World
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tempus AI (NASDAQ:TEM) Shares Down 5.3% - Defense World
Deeper Dive: Understanding Tempus AI Inc. (TEM) Through its Various Ratios - The Dwinnex
Just the Facts: Tempest Minerals begins fieldwork at Five Wheel Project - Proactive Investors UK
Tempus AI Inc. [TEM] Investment Guide: What You Need to Know - Knox Daily
Keeping an Eye on Tempest Therapeutics Inc (TPST) After Insider Trading Activity - Knox Daily
An analyst sees good growth prospects for Tempus AI Inc. (TEM) - SETE News
Tempest Further Strengthens Leadership Team with - GlobeNewswire
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs - StockTitan
Tempest Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Tempest Therapeutics Inc (TPST) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):